HYDROFARM HOLDINGS GROUP, INC. quarterly report, Q1 FY2024

Hydrofarm Holdings Group, Inc. — Q1 2024 Form 10-Q

Business context and period. Hydrofarm manufactures and distributes hydroponics and controlled-environment agriculture equipment and supplies, primarily in the U.S. and Canada. This unaudited report covers the three months ended March 31, 2024; amounts below are in U.S. dollars.

Financial performance and position

MetricQ1 2024Q1 2023 / prior date
Net sales$54.2 million$62.2 million
Gross profit / margin$10.9 million / 20.2%$11.4 million / 18.3%
SG&A$19.6 million$24.4 million
Operating loss$8.7 million$13.1 million
Net loss$12.6 million; $0.28 per share$16.8 million; $0.37 per share
Cash from operations$(2.3) million$(9.0) million
Capital expenditures / investing cash flow$1.4 million / $(1.4) million$1.7 million / $(1.6) million
Cash and equivalents$24.2 million$30.3 million at Dec. 31, 2023
Debt$120.5 million Term Loan principal; $116.7 million total debt carrying value$122.5 million Term Loan principal at Dec. 31, 2023

Gross margin improved despite lower sales. The company reported $116.7 million of total liabilities and $278.0 million of stockholders’ equity at quarter-end. It had no Revolving Credit Facility borrowings and reported approximately $25 million available to borrow before the minimum fixed-charge coverage covenant applies. Operating lease liabilities totaled $53.5 million and finance lease liabilities $9.4 million. The Term Loan’s effective interest rate was 12.03% for the quarter.

Material changes and management commentary

  • Sales fell 12.9% year over year, driven mainly by a 12.6% decline in volume and mix; pricing declined 0.3%. Management attributed weaker demand primarily to agricultural oversupply and lower cannabis wholesale prices, which have reduced cultivation activity.
  • Gross margin rose to 20.2% from 18.3%, which management attributed primarily to restructuring and improved manufacturing productivity. SG&A declined 19.7%, reflecting lower facility, professional-services, insurance, and compensation costs.
  • Net loss narrowed by $4.2 million year over year. Interest expense increased $0.2 million, primarily due to higher variable rates on the Term Loan.
  • Operating cash use improved to $2.3 million from $9.0 million. Cash declined $6.2 million during the quarter, including $2.0 million of Term Loan repayments. Management cited normal first-quarter seasonal working-capital needs.

Outlook, risks, and unusual items

  • Management expects cash from operations, cash on hand, and revolver availability to support operations, debt service, capital spending, leases, and working capital for the next 12 months, but cautioned that future cash generation and borrowing availability are not assured. No formal revenue or earnings guidance is provided in the filing.
  • The second restructuring phase is expected to incur more than $2.0 million of additional charges over the next several quarters, including more than $1.0 million of estimated cash costs. Management estimates approximately $1.5 million in annualized savings, while warning savings may not be fully realized.
  • After quarter-end, the company agreed to sell certain durable-equipment manufacturing assets for approximately $8.7 million; the assets include an estimated $16.0 million of inventory, property, equipment, and other assets. The sale is expected to close in Q2 2024 and is estimated to produce a roughly $12.0 million loss. Hydrofarm intends to continue selling the affected proprietary products through an exclusive supply agreement. It plans to use proceeds for permitted reinvestment or offer them toward Term Loan prepayment, and to terminate approximately $1.3 million of operating lease and $0.7 million of equipment finance lease obligations.
  • On March 14, 2024, Nasdaq notified the company that its share price had failed the $1.00 minimum bid-price requirement for 30 consecutive business days. The compliance period runs through September 10, 2024; continued listing is not assured.
  • The variable-rate Term Loan exposes the company to rate increases; management estimates a 100-basis-point increase would raise annual interest expense by approximately $1.1 million. The company does not currently hedge interest-rate risk.
  • Management reported compliance with debt covenants at March 31, 2024. It did not expect ordinary-course legal claims to have a material adverse effect. The filing also notes potential future inventory, receivables, and long-lived-asset charges if adverse market conditions persist.

Important facts for investors to verify

  • Whether demand and sales stabilize amid continued cannabis-industry oversupply, and whether margin gains persist as volume declines.
  • Actual restructuring charges, cash costs, and realized savings versus management’s estimates.
  • Closing terms and proceeds from the durable-assets sale, the estimated loss, lease exits, and use of net proceeds under the Term Loan.
  • Cash burn, working-capital trends, revolver availability, and covenant headroom, particularly as the business approaches seasonal cash needs.
  • Progress toward Nasdaq’s minimum bid-price requirement and any effect on the stock’s listing or financing options.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.